LHDX · Categories · Earnings
LHDX - Earnings announcements
Lucira Health Inc. (LHDX) earnings announcements - real-time wire coverage filtered to Earnings only.
Recent Earnings for LHDX
- Lucira Health Announces Third Quarter 2022 Results and Provides Business UpdatesEMERYVILLE, Calif., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Lucira Health, Inc. (NASDAQ:LHDX) ("Lucira Health," "Lucira" or the "Company"), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease tests, today reported financial results for the third quarter ended September 30, 2022 and provided business updates. Recent Highlights Achieved net revenue of $34.4 million for the third quarter of 2022, an increase of 130% over the third quarter of 2021.Executed a marketing agreement with Pfizer to increase awareness of the risks of COVID-19 and the availability of treatment. Partnered with telehealth marketplace, Sesame Care
- Lucira Health to Announce Third Quarter 2022 Financial ResultsEMERYVILLE, Calif., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Lucira Health, Inc. ("Lucira Health" or "Lucira"), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease tests, and a digital health platform that will connect patients with providers, today announced that the company will report third quarter 2022 financial results on, Monday, November 14th, 2022. Lucira's management will host a conference call and webcast at 1:30 p.m. PT / 4:30 p.m. ET that day to discuss the financial results and provide a corporate update. Conference Call and Webcast DetailsInvestors interested in listening to the conference call should reg
- Lucira Health Announces Second Quarter 2022 Results and Provides Business UpdatesEMERYVILLE, Calif., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Lucira Health, Inc. (NASDAQ:LHDX) ("Lucira Health," "Lucira" or the "Company"), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease tests, today reported financial results for the second quarter ended June 30, 2022 and provided business updates. Recent Highlights Achieved net revenue of $26.1 million for the second quarter of 2022, an increase of 110% over the second quarter of 2021Received regulatory approval in Canada for the COVID-19 & Flu test with Self Test at Home indication and a full exemption by the New Zealand Ministry of Health for COVID-19 testSc
- Lucira Health to Announce Second Quarter 2022 Financial ResultsEMERYVILLE, Calif., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Lucira Health, Inc. ("Lucira Health" or "Lucira"), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits, today announced that the company will report second quarter 2022 financial results on, Monday, August 15, 2022. Lucira's management will host a conference call and webcast at 1:30 p.m. PT / 4:30 p.m. ET that day to discuss the financial results and provide a corporate update. Conference Call and Webcast DetailsInvestors interested in listening to the conference call should register online. Participants are required to register a day in advance or
- Lucira Health Announces First Quarter 2022 Results and Business UpdateEMERYVILLE, Calif., May 12, 2022 (GLOBE NEWSWIRE) -- Lucira Health, Inc. (NASDAQ:LHDX) ("Lucira Health," "Lucira" or the "Company"), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease tests, today reported financial results and provided business updates for the first quarter ended March 31, 2022. Recent Highlights Achieved net revenue of $90.5 million for the first quarter of 2022, equivalent to 97% of fiscal year 2021 net revenueRecorded first-time net income of $13.1 million Entered into a debt facility agreement up to $80 million with Silicon Valley Bank and Hercules Capital; drew down first tranche of $30
- Lucira Health to Announce First Quarter 2022 Financial ResultsEMERYVILLE, Calif., April 28, 2022 (GLOBE NEWSWIRE) -- Lucira Health, Inc. ("Lucira Health" or "Lucira"), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits, today announced that the company will report first quarter 2022 financial results on Thursday, May 12, 2022. Lucira's management will host a conference call and webcast at 1:30 p.m. PT / 4:30 p.m. ET that day to discuss the financial results and provide a corporate update. Conference Call and Webcast DetailsThe conference call can be accessed by dialing (833) 562-0151 for participants in the U.S. or Canada and (661) 567-1232 for international cal
- Lucira Health Announces Fourth Quarter and Full Year 2021 Results and Reaffirms 2022 Financial OutlookEMERYVILLE, Calif., March 10, 2022 (GLOBE NEWSWIRE) -- Lucira Health, Inc. (NASDAQ:LHDX) ("Lucira Health," "Lucira" or the "Company"), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits, today reported financial results for the fourth quarter and full year ended December 31, 2021. Recent Highlights Achieved net revenue of $61.1 million for the fourth quarter of 2021, representing approximately 300% sequential growth over the preceding quarterRecorded full year revenue of $93.1 million for 2021, the Company's first full year of commercializationIncreased manufacturing output through the Dominican Repu
- Lucira Health to Announce Fourth Quarter 2021 Financial ResultsEMERYVILLE, Calif., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Lucira Health, Inc. ("Lucira Health" or "Lucira") (NASDAQ:LHDX), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits, today announced that the company will report fourth quarter 2021 financial results on, Thursday, March 10, 2022. Lucira's management will host a conference call and webcast at 1:30 p.m. PT / 4:30 p.m. ET that day to discuss the financial results and provide a corporate update. Conference Call and Webcast DetailsThe conference call can be accessed by dialing (833) 562-0151 for participants in the U.S. or Canada and (661) 567-1232 for
- Lucira Health Announces Third Quarter 2021 Financial Results and Provides Business UpdateEMERYVILLE, Calif., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Lucira Health, Inc. (NASDAQ:LHDX) ("Lucira Health," "Lucira" or the "Company"), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits, today reported financial results for the third quarter ended September 30, 2021 and provided business updates. Highlights Recorded record-high revenue of $15.0 million for the third quarter of 2021, representing 21% sequential growth from the previous quarter of 2021Reopened online sales of its OTC LUCIRA CHECK IT COVID-19 Test Kit via the Company's website and on AmazonReceived Pandemic Special Access Route ("PSAR")
- Lucira Health to Announce Third Quarter 2021 Financial ResultsEMERYVILLE, Calif., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Lucira Health, Inc. ("Lucira Health" or "Lucira"), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits, today announced that the company will report third quarter 2021 financial results on, Thursday, November 11, 2021. Lucira's management will host a conference call and webcast at 1:30 p.m. PT / 4:30 p.m. ET that day to discuss the financial results and provide a corporate update. Conference Call and Webcast DetailsThe conference call can be accessed by dialing (833) 562-0151 for participants in the U.S. or Canada and (661) 567-1232 for internationa
- Lucira Health Announces Second Quarter 2021 Financial ResultsEMERYVILLE, Calif., Aug. 12, 2021 (GLOBE NEWSWIRE) -- Lucira Health, Inc. (NASDAQ:LHDX) ("Lucira Health," "Lucira" or the "Company"), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits, today reported financial results for the second quarter ended June 30, 2021. Recent Highlights Recorded record-high revenue of $12.4 million for the second quarter of 2021, representing 175% sequential growth from the previous quarter of 2021Commenced sale of LUCIRA CHECK IT COVID-19 Test Kit through OTC channels, which does not require a physician's prescriptionInternational demand fueled by OTC indicationNew product